<p>Multiple Sclerosis: Advances in Clinical Trial Design, Treatment and Future Perspectives is a review of therapeutic developments for a disease that is one of the major problems in current neurologic practice. Progress in this field has been rapid and there have been important developments in clin
Treatment of Multiple Sclerosis: Trial Design, Results, and Future Perspectives
β Scribed by George W. Ellison (auth.), Richard A. Rudick MD, Donald E. Goodkin MD (eds.)
- Publisher
- Springer-Verlag London
- Year
- 1992
- Tongue
- English
- Leaves
- 323
- Series
- Clinical Medicine and the Nervous System
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
Multiple sclerosis is one of the major current problems in neurolΒ ogical practice. It remains incompletely understood, yet is a common cause of chronic disability in developed Western soΒ cieties: Patients with the disease have difficulty understanding what has happened to them and become bewildered by the conΒ trast between the evidently large body of knowledge concerning the clinical manifestations and course of the disease, and the conflicting views they so often receive from different specialists as to the best current management of their disease. As in so many disorders for which treatment is only partially effective, at best, "alternative" therapies abound. Dr. Rudick and Dr. Goodkin have extensive experience in the day-to-day management of multiple sclerosis at the Mellen Center for Multiple Sclerosis Treatment and Research, attached to the Cleveland Clinic. In this book they have assembled a group of experts from several countries and have provided a comprehensive review of the results of different treatments of the disease. Each treatment is considered in the light of its proposed scientific basis or mode of action, and in relation to ethical and trial design issues. This information deserves to be made widely available. As the treatment of multiple sclerosis enters a new era as a result of the new understanding of the cellular mechanisms of demyelination and the molecular biology of the immune response, this information about current treatments assumes additional importance. The book is of interest to all physicians concerned with the management of patients with the disease.
β¦ Table of Contents
Front Matter....Pages i-xviii
Experimental Therapies for Multiple Sclerosis: Historical Perspective....Pages 1-15
The Natural History of Multiple Sclerosis....Pages 17-45
Assessing the Outcome of Experimental Therapies in Multiple Sclerosis Patients....Pages 47-90
Design and Statistical Issues Related to Testing Experimental Therapy in Multiple Sclerosis....Pages 91-122
Pathogenesis of Multiple Sclerosis: Relationship to Therapeutic Strategies....Pages 123-133
Treatment of Multiple Sclerosis with ACTH and Corticosteroids....Pages 135-156
Treatment of Multiple Sclerosis with Azathioprine....Pages 157-172
Treatment of Multiple Sclerosis with Copolymer I....Pages 173-198
Treatment of Multiple Sclerosis with Cyclophosphamide....Pages 199-216
Treatment of Multiple Sclerosis with Cyclosporine A....Pages 217-232
Treatment of Multiple Sclerosis with Interferons....Pages 233-250
Treatment of Multiple Sclerosis with Plasma Exchange....Pages 251-266
Total Lymphoid Irradiation in Multiple Sclerosis....Pages 267-279
Specific Immunotherapeutic Strategies: Lessons from Myelin Basic Protein-Induced Experimental Allergic Encephalomyelitis....Pages 281-299
Experimental Approaches to Specific Immunotherapy in Multiple Sclerosis....Pages 301-307
Back Matter....Pages 309-313
β¦ Subjects
Neurology; Statistics for Life Sciences, Medicine, Health Sciences; Neurosciences
π SIMILAR VOLUMES
<p><p>The availability of powerful genome-wide association study technology, during the last five years, has shown that most of the βnewβ MS susceptibility loci are immune-response genes. It is clear that there is much novelty in the field of MS immunology, which has served as an impetus to invest i
<P>In multiple sclerosis (MS), conventional magnetic resonance imaging (cMRI) has proved to be a valuable tool to increase diagnostic confidence and for monitoring the efficacy of experimental treatment. However, cMRI has limited specificity and accuracy of cMRI to the most disabling aspects of the
<p>The recent explosion of new information about the pathology, pathophysiology, clinical classification, imaging, and treatment of multiple sclerosis (MS) has dramatically opened the way to a deeper understanding of the disease and a more effective therapeutic landscape for patients. In Multiple Sc